SATISFY: Assessment of the Satisfaction of Patient Undergoing Opioid Replacement Therapy Toward Their Management in Community Pharmacy

Sponsor
University Hospital, Clermont-Ferrand (Other)
Overall Status
Completed
CT.gov ID
NCT03961789
Collaborator
UFR de Pharmacie (Clermont-Ferrand) (Other)
98
1
15.7
6.3

Study Details

Study Description

Brief Summary

The patient's compliance to his medication therapy, and therefore the success of the treatment, is particularly related to his pharmacy management. Thus, the satisfaction of an individual in their interview with the pharmacist is a very important element.

The pharmacist in his professional activity may have to manage patients with opioid related disorders. Pharmacist activity will result in the dispensing of opioid replacement therapy (ORT), single-use syringes, harm reduction kits and prevention advices for the reduction of toxicity and infection risks.

Since the 1990s, the consumption of ORT has been steadily increasing. According to the OFDT (French Observatory of Drugs and Drug Addiction), the number of patients undergoing ORT is about 150 000 patients. Since high-dose buprenorphine is prescribed for approximately two-thirds of patients, it remains the most frequently prescribed ORT in France.

Recently, a French association assisting drug users (ASUD - Auto-support des usagers de drogues) performed a study in Paris (20/07/2018 - 25/08/2018) to assess the delivery of opioid replacement therapies by community pharmacists. In this study, 71% of pharmacists refused to deliver opioid replacement therapies. The main reasons reported were security (56%) and activity saturation, meaning that pharmacists considered that they had too many patients using opioid drugs. In France, the refusal of a pharmacist to deliver drugs is a punishable offence. According to the Code of ethics of pharmacists, pharmacists must respect life and people without discrimination. Pharmacists have a low perception of patients suffering from opioid addiction. Another study performed by ASUD in 93 community pharmacies, showed that pharmacists used the term "toxicomaniacs" instead of "drug users". Most pharmacists had had a bad experience with drugs users, with physical and verbal aggressions. The conclusions of this study showed that pharmacists lacked knowledge of drug users and drug use. Pharmacists knew about harm reduction kits for opioid users (containing sterile syringes, needles, water, antiseptics, etc.) and had already opened them, but very few knew how to use them. More worryingly, some pharmacists did not understand the harm reduction strategies available It thus appears that community pharmacists have a difficult relationship with patient suffering of opioid related disorders, which can have an impact on patient's satisfaction.

The objective of this study will be to assess the satisfaction of patients undergoing ORT regarding their management by community pharmacists.

Condition or Disease Intervention/Treatment Phase
  • Other: patients undergoing opioid replacement therapy

Detailed Description

Patients will be recruited in addiction departments, associations for risk management and general practitioners, and a paper questionnaire will be sent to the patients. The questionnaire is anonymous.

Study Design

Study Type:
Observational
Actual Enrollment :
98 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Assessment of the Satisfaction of Patient Undergoing Opioid Replacement Therapy Toward Their Management in Community Pharmacy - SATISFY: a Cross-sectional Study
Actual Study Start Date :
Jan 29, 2018
Actual Primary Completion Date :
May 21, 2019
Actual Study Completion Date :
May 21, 2019

Arms and Interventions

Arm Intervention/Treatment
cohorte 1

patients undergoing opioid replacement therapy

Other: patients undergoing opioid replacement therapy
patients undergoing opioid replacement therapy
Other Names:
  • no intervention or other
  • Outcome Measures

    Primary Outcome Measures

    1. Score of satisfaction [day 1]

      visual analogic scale (VAS) "Are you satisfied with your management by community pharmacists?" 0: not satisfied - 100: totally satisfied

    Secondary Outcome Measures

    1. Prevention tips given by the pharmacist: risk of infection, overdose, way of using drugs, adverse effects and drug interactions [day 1]

      yes/no

    2. Services rendered by the pharmacist: sale of sterile equipment, management of soiled waste, dispensing of opioid replacement therapy [day 1]

      yes/no

    3. Perception of the profile / behaviour of pharmacists: welcoming and open to discussion [day 1]

      VAS, 0: not at all - 100 : totally

    4. Perception of the profile / behaviour of pharmacists: respect for confidentiality [day 1]

      VAS, 0: not at all - 100 : totally

    5. Perception of the profile / behaviour of pharmacists: competent [day 1]

      VAS, 0: not at all - 100 : totally

    6. opioid replacement therapy [day 1]

      name, dose, route

    7. Number of physician consulted for the last 6 months [day 1]

      number

    8. Number of community pharmacy consulted for the last 6 months [day 1]

      number

    9. duration of opioid use disorder [day 1]

      number of years/months

    10. Demographic information [day 1]

      : age, sex, study level, marital status, health care insurance, monthly income, type of housing

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient undergoing opioid replacement therapy
    Exclusion Criteria:
    • Age <18 years

    • Patient unable to understand or write in French

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CHU de Clermont-Ferrand Clermont-Ferrand France 63000

    Sponsors and Collaborators

    • University Hospital, Clermont-Ferrand
    • UFR de Pharmacie (Clermont-Ferrand)

    Investigators

    • Principal Investigator: David Balayssac, University Hospital, Clermont-Ferrand

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Clermont-Ferrand
    ClinicalTrials.gov Identifier:
    NCT03961789
    Other Study ID Numbers:
    • CHU-434
    First Posted:
    May 23, 2019
    Last Update Posted:
    Jan 14, 2022
    Last Verified:
    Dec 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Clermont-Ferrand
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 14, 2022